PURE Bioscience, Inc. (PURE)
| Previous close | 0.0790 |
| Open | 0.0710 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0700 - 0.0770 |
| 52-week range | 0.0600 - 0.1700 |
| Volume | |
| Avg. volume | 22,925 |
| Market cap | 7.83M |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 12 Jun 2024 - 17 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WirePURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results
EL CAJON, Calif., March 18, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2024.
Business WirePURE Bioscience Reports Fiscal First Quarter 2024 Financial Results
EL CAJON, Calif., December 14, 2023--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2023.
Business WirePURE Bioscience Reports Fiscal 2023 Financial Results
EL CAJON, Calif., October 30, 2023--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.
